Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name 4r,6r-dorzolamide
Drug ID BADD_D00006
Description Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension.[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.[A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.[A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]
Indications and Usage For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
Marketing Status Prescription; Discontinued
ATC Code S01EC03
DrugBank ID DB00869
KEGG ID D07871
MeSH ID C062765
PubChem ID 92087
TTD Drug ID D05UYW
NDC Product Code 14445-404; 70377-081
Synonyms dorzolamide | 4-ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide | 5,6-dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | dorzolamide, (trans)-isomer | Dorzolamide Chibret | MK 507 | MK-507 | Trusopt | dorzolamide hydrochloride | L 671152 | L-671,152
Chemical Information
Molecular Formula C10H16N2O4S3
CAS Registry Number 120279-89-2
SMILES CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Gastrointestinal pain07.01.05.005--
Hallucination19.10.02.002--
Headache17.14.01.001--
Hepatomegaly09.01.05.001--Not Available
Hyperglycaemia05.06.02.002; 14.06.02.002--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoaesthesia eye06.01.01.007; 17.02.06.019--Not Available
Hypoglycaemia05.06.03.001; 14.06.03.001--
Hypotension24.06.03.002--
Influenza11.05.03.001; 22.07.02.001--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Intermittent claudication24.04.03.001--Not Available
Iridocyclitis06.04.03.001--Not Available
Keratitis06.04.02.002--
Lacrimation increased06.08.02.004--
Laryngospasm22.04.02.002--
Lenticular opacities06.06.01.003--Not Available
Libido decreased19.08.03.001; 21.03.02.005--
Local reaction08.01.03.012--Not Available
Loss of consciousness17.02.04.004--Not Available
Mood swings19.04.03.001--Not Available
Myasthenia gravis10.04.05.001; 15.05.08.001; 17.05.04.001--
Myocardial infarction02.02.02.007; 24.04.04.009--
Myopia06.02.04.002--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages